Objective: To retrospectively analyze the monitoring results of plasma concentration of cyclosporin A（CsA）

and to provide a reference for safe

effective

and rational use of CsA in clinical practice. Methods: The whole-blood CsA concentration results and monitoring data were collected from 550 patients who had undergone enzyme-amplified immunoassay in our hospital from 2017 to 2018. A statistical analysis was performed on the monitorignrog uppas.tt eRrne saunltds :f rTehqeu emnocny

it odrriungg pdaotstee

r np loafs mCsa Ac ownacse nmtariantiloyn p rraen-gdeo

s ea ntrdo ucgohn ccoomnicteannttr atmioendi cmaotinoitnosr ionfg p（a8 t5 i.e1 nt%）s.u Ibnthe three types of patients monitored

the monitoring frequency of post-kidney transplantation（PKT） patients and those with nephrotic syndrome（NS） was higher than that of those with aplastic anemia（AA）. The mean number of measurements per person and concentration attainment rate（90.6%） were highest in PKT patients

while the monitoring attainment rates of patients with NS and AA were less than 40%. There were significant differences in the mean dose administered and trough concentration between the three types of patients

with the highest values observed in patients with AA. All patients had concomitant medications

with the highest mean number of concomitant medications observed in patients with NS. Conclusion: It is of great significance for rational use of CsA to emphasize drug monitoring and control and closely monitor the dose of CsA based on individual patient’s disease.